Sign up to save your podcasts
Or
Share Leveraging Clinical Data: HER2-Targeted ADCs in Second-Line and Beyond MBC
Share to email
Share to Facebook
Share to X
Share to email
Share to Facebook
Share to X
Or
Leveraging Clinical Data: HER2-Targeted ADCs in Second-Line and Beyond MBC
CME credits: 1.00
Valid until: 18-06-2026
Claim your CME credit at https://reachmd.com/programs/cme/leveraging-clinical-data-her2-targeted-adcs-in-second-line-and-beyond-mbc/29946/
The development and availability of HER2-directed therapies has dramatically improved outcomes for patients with metastatic breast cancer (MBC). Moreover, emerging data indicate that these therapies also improve outcomes for those with brain metastasis. In this educational series, expert faculty differentiate the available HER2-directed therapies for MBC, assess their efficacy in disease with brain metastasis, and review treatment selection and sequencing considerations for these agents.
View all episodes
By ReachMD
4.3
33 ratings
CME credits: 1.00
Valid until: 18-06-2026
Claim your CME credit at https://reachmd.com/programs/cme/leveraging-clinical-data-her2-targeted-adcs-in-second-line-and-beyond-mbc/29946/
The development and availability of HER2-directed therapies has dramatically improved outcomes for patients with metastatic breast cancer (MBC). Moreover, emerging data indicate that these therapies also improve outcomes for those with brain metastasis. In this educational series, expert faculty differentiate the available HER2-directed therapies for MBC, assess their efficacy in disease with brain metastasis, and review treatment selection and sequencing considerations for these agents.